Navigation Links
Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
Date:9/2/2008

- No Currently Approved Drugs to Treat Hepatorenal Syndrome Type 1 in U.S.

-

CLINTON, N.J. and LEBANON, N.J., Sept. 2 /PRNewswire/ -- Ikaria Holdings, Inc. and Orphan Therapeutics, LLC announced today that they have entered into an agreement under which Ikaria has acquired rights to LUCASSIN(R) (terlipressin) in North America from Orphan Therapeutics.

Orphan Therapeutics has initiated a rolling NDA with the U.S. Food and Drug Administration (FDA) seeking marketing approval for LUCASSIN for the treatment of hepatorenal syndrome (HRS) Type 1. LUCASSIN has been granted orphan drug status and fast-track designation. Following marketing approval of LUCASSIN, Orphan Therapeutics will transfer North American rights to Ikaria, which will then be responsible for its post-market development and commercialization.

HRS Type 1 is the development of kidney failure in patients with late-stage liver cirrhosis in the absence of any other cause. It is characterized by rapid onset of renal failure with a high mortality rate that exceeds 80% within three months.

"The acquisition of LUCASSIN reinforces our corporate mission to deliver novel treatments in areas of unmet medical need within the underserved critical care market," commented Daniel Tasse, President and CEO of Ikaria. "We look forward to working with Orphan Therapeutics to provide a promising therapy to patients with this life-threatening condition."

"Ikaria's focus on therapies for patients in critical care makes it an ideal partner for LUCASSIN," said Peter Teuber, Ph.D., President of Orphan Therapeutics. "We are very pleased to be working with Ikaria towards our goal to make LUCASSIN available for HRS Type 1 patients in the U.S., who currently have no approved drugs available to them."

LUCASSIN is a synthetic vasopressin analogue that acts via the vasopressin V1 receptor as a systemic vasoconstrictor, which appears to increase effective ar
'/>"/>

SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Ikaria(R) Strengthens Research & Development Team
2. Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market
3. Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events
4. Clinix Acquires MedicWare, Inc.
5. Catholic Health East Acquires Saint Michaels Medical Center
6. Genomma Lab Internacional Acquires UNIGASTROZOL
7. Valley National Gases, LLC Acquires Beaver Valley Welding Supply, Inc: Sixth Acquisition for Valley National Gases This Fiscal Year
8. Grubb & Ellis Healthcare REIT Acquires Senior Care Portfolio 1 in Calif.
9. Vibra Healthcare Acquires two Hospitals in Southern California
10. Manhattan Scientifics Acquires Metallicum, Inc.
11. Grubb & Ellis Healthcare REIT Acquires Decatur Medical Plaza in Decatur, Ga.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 1Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 2Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 3Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 4Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5466 5Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 1Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 2Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 3Video 3A EmFinders EmSeeQ 28TM 29 Now Available to Locate Wandering Individuals in Emergency Situations Nationwide 5461 4